mCRPC patients receiving 225Ac-PSMA-617 therapy in post androgen deprivation therapy setting: response to treatment and survival analysis

Treatment with prostate-specific membrane antigen–targeted therapy ²²⁵Ac-PSMA-617 administered immediately following androgen-deprivation therapy among 53 patients with metastatic castration-resistant prostate cancer demonstrated a more than 50% decrease in prostate-specific antigen level in 91% of patients and a decline of any level in 96%, according to data from a recent clinical trial.